Concourse Financial Group Securities, Inc. Arrowhead Pharmaceuticals, Inc. Transaction History

Concourse Financial Group Securities, Inc.

  • $1.64 Billion
  • Q3 2024
Number of Shares
0
Previous 0 NaN%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024
BUY
$19.36 - $29.54 $0 - $0
0 New
0 $0
Q2 2024

Jul 23, 2024
BUY
$21.87 - $28.24 $0 - $0
0 New
0 $0
Q1 2024

Apr 30, 2024
BUY
$27.21 - $39.48 $0 - $0
0 New
0 $0
Q4 2023

Feb 07, 2024
BUY
$21.2 - $31.03 $0 - $0
0 New
0 $0
Q3 2023

Oct 30, 2023
BUY
$26.2 - $36.08 $0 - $0
0 New
0 $0
Q3 2023

Oct 25, 2023
SELL
$26.2 - $36.08 $26 - $36
-1 Closed
0 $0
Q1 2023

May 15, 2023
BUY
$23.68 - $38.51 $23 - $38
1 New
1 $0
Q4 2022

Jan 30, 2023
BUY
$28.0 - $40.56 $0 - $0
0 New
0 $0
Q3 2022

Nov 15, 2022
BUY
$29.63 - $48.31 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022
BUY
$27.79 - $50.61 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022
SELL
$39.62 - $69.97 $356 - $629
-9 Closed
0 $0
Q4 2020

Feb 02, 2021
SELL
$43.82 - $85.37 $3,330 - $6,488
-76 Reduced 89.41%
9 $1,000
Q1 2020

May 13, 2020
SELL
$20.56 - $63.12 $1,007 - $3,092
-49 Reduced 36.57%
85 $2,000
Q4 2019

Feb 14, 2020
BUY
$28.14 - $73.01 $3,770 - $9,783
134 New
134 $9,000
Q3 2019

Nov 13, 2019
SELL
$26.26 - $34.86 $3,545 - $4,706
-135 Closed
0 $0
Q2 2019

Aug 13, 2019
BUY
$17.43 - $28.82 $139 - $230
8 Added 6.3%
135 $4,000
Q1 2019

May 15, 2019
SELL
$12.05 - $20.18 $530 - $887
-44 Reduced 25.73%
127 $2,000
Q4 2018

Feb 14, 2019
BUY
$10.74 - $19.7 $1,836 - $3,368
171 New
171 $2,000
Q3 2018

Nov 13, 2018
BUY
$14.0 - $20.3 $0 - $0
0 New
0 $0

Others Institutions Holding ARWR

# of Institutions
294
Shares Held
91M
Call Options Held
1.28M
Put Options Held
503K
View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

ARWR Quotes by TradingView
  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.28B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email